(EVLV) Evolv Technologies Holdings - Overview
Sector: Industrials | Industry: Security & Protection Services | Exchange: NASDAQ (USA) | Market Cap: 1.009m USD | Total Return: 3.8% in 12m
Avg Turnover: 18.7M
Qual. Beats: 0
Rev. Trend: 98.8%
Qual. Beats: 1
Warnings
Interest Coverage Ratio -21.0 is critical
Altman Z'' -7.24 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
Evolv Technologies Holdings, Inc. (EVLV) focuses on AI-based security screening and weapons detection. The company designs and markets hardware-software solutions, including Evolv Express and Evolv eXpedite, to identify firearms and explosives in high-traffic environments without disrupting the flow of people. Its product suite is supported by a proprietary analytics application that provides venue operators with data on visitor arrivals and system performance.
The company operates within the broader physical security market, which is increasingly shifting from passive metal detection to proactive, sensor-fusion technologies. EVLV utilizes a hardware-as-a-service (HaaS) business model, generating recurring revenue through multi-year subscriptions that include software updates and data analytics.
The firm serves a diverse client base across sectors such as professional sports, healthcare, education, and government facilities. For a deeper analysis of the companys valuation and growth metrics, ValueRay offers additional quantitative tools. Evolv Technologies is headquartered in Waltham, Massachusetts, and has been operational since 2013.
- Subscription-based recurring revenue growth from Evolv Express installations
- School and stadium safety mandates drive regional market penetration
- High hardware manufacturing costs impact short-term gross margin expansion
- Internal control weaknesses and financial restatements affect investor confidence
- AI detection accuracy rates influence competitive positioning against traditional screening
| Net Income: -36.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA 15.06 > 1.0 |
| NWC/Revenue: 16.30% < 20% (prev 8.22%; Δ 8.08% < -1%) |
| CFO/TA 0.06 > 3% & CFO 18.0m > Net Income -36.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (177.1m) vs 12m ago 10.10% < -2% |
| Gross Margin: 49.90% > 18% (prev 0.58%; Δ 4.93k% > 0.5%) |
| Asset Turnover: 57.16% > 50% (prev 44.54%; Δ 12.62% > 0%) |
| Interest Coverage Ratio: -21.05 > 6 (EBITDA TTM -31.1m / Interest Expense TTM 2.69m) |
| A: 0.09 (Total Current Assets 152.0m - Total Current Liabilities 125.9m) / Total Assets 304.6m |
| B: -1.29 (Retained Earnings -392.8m / Total Assets 304.6m) |
| C: -0.20 (EBIT TTM -56.7m / Avg Total Assets 280.3m) |
| D: -2.13 (Book Value of Equity -392.5m / Total Liabilities 184.0m) |
| Altman-Z'' = -7.24 = D |
| DSRI: 0.88 (Receivables 43.9m/35.4m, Revenue 160.2m/114.0m) |
| GMI: 1.16 (GM 49.90% / 58.04%) |
| AQI: 1.21 (AQ_t 0.04 / AQ_t-1 0.04) |
| SGI: 1.41 (Revenue 160.2m / 114.0m) |
| TATA: -0.18 (NI -36.5m - CFO 18.0m) / TA 304.6m) |
| Beneish M = -2.74 (Cap -4..+1) = A |
As of May 24, 2026, the stock is trading at USD 6.00 with a total of 2,666,404 shares traded.
Over the past week, the price has changed by +9.47%,
over one month by -7.96%,
over three months by +27.35% and
over the past year by +3.83%.
Evolv Technologies Holdings has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy EVLV.
- StrongBuy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 10.1 | 68.8% |
P/S = 6.2978
P/B = 8.362
Revenue TTM = 160.2m USD
EBIT TTM = -56.7m USD
EBITDA TTM = -31.1m USD
Long Term Debt = 28.6m USD (from longTermDebt, last fiscal year)
Short Term Debt = 3.12m USD (from shortTermDebt, last quarter)
Debt = 55.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 13.6m
Net Debt = -5.46m USD (calculated: Debt 55.6m - CCE 61.1m)
Enterprise Value = 1.00b USD (1.01b + Debt 55.6m - CCE 61.1m)
Interest Coverage Ratio = -21.05 (Ebit TTM -56.7m / Interest Expense TTM 2.69m)
EV/FCF = -94.91x (Enterprise Value 1.00b / FCF TTM -10.6m)
FCF Yield = -1.05% (FCF TTM -10.6m / Enterprise Value 1.00b)
FCF Margin = -6.60% (FCF TTM -10.6m / Revenue TTM 160.2m)
Net Margin = -22.75% (Net Income TTM -36.5m / Revenue TTM 160.2m)
Gross Margin = 49.90% ((Revenue TTM 160.2m - Cost of Revenue TTM 80.3m) / Revenue TTM)
Gross Margin QoQ = 51.37% (prev 48.38%)
Tobins Q-Ratio = 3.29 (Enterprise Value 1.00b / Total Assets 304.6m)
Interest Expense / Debt = 4.84% (Interest Expense 2.69m / Debt 55.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -44.8m (EBIT -56.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.21 (Total Current Assets 152.0m / Total Current Liabilities 125.9m)
Debt / Equity = 0.46 (Debt 55.6m / totalStockholderEquity, last quarter 120.7m)
Debt / EBITDA = 0.18 (negative EBITDA) (Net Debt -5.46m / EBITDA -31.1m)
Debt / FCF = 0.52 (negative FCF - burning cash) (Net Debt -5.46m / FCF TTM -10.6m)
Total Stockholder Equity = 108.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -13.01% (Net Income -36.5m / Total Assets 304.6m)
RoE = -7.27% (Net Income TTM -36.5m / Total Stockholder Equity 501.6m)
RoCE = -10.69% (EBIT -56.7m / Capital Employed (Equity 501.6m + L.T.Debt 28.6m))
RoIC = -37.06% (negative operating profit) (NOPAT -44.8m / Invested Capital 120.8m)
WACC = 10.42% (E(1.01b)/V(1.06b) * Re(10.78%) + D(55.6m)/V(1.06b) * Rd(4.84%) * (1-Tc(0.21)))
Discount Rate = 10.78% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 77.78 | Cagr: 7.30%
[DCF] Fair Price = unknown (Cash Flow -10.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.28 | # QB: 0
Revenue Correlation: 98.81 | Revenue CAGR: 32.31% | SUE: 0.90 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.02 | Chg30d=N/A | Revisions=+0% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.02 | Chg30d=N/A | Revisions=-20% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.06 | Chg30d=+5.10% | Revisions=-20% | GrowthEPS=+36.7% | GrowthRev=+21.4%
EPS next Year (2027-12-31): EPS=-0.03 | Chg30d=N/A | Revisions=-20% | GrowthEPS=+52.6% | GrowthRev=+18.1%
[Analyst] Revisions Ratio: -20%